Considering breast cancer-associated mutations across a broader range of genes (BRCA1, BRCA2, PALB2, and the more moderate-risk genes, ATM and CHEK2), the average carrier risk is equivalent to the top 3% of the PRS distribution (S8B Fig, see S1 File for definition of mutation carriers). This evidence concerns the gene CHEK2 and breast cancer.